A Phase III Multinational, Multicenter, Observer-Blinded, Randomized, Active-Controlled Trial to Evaluate the Immunogenicity and Safety of the Preventive COVID-19 Vaccine AdCLD-CoV19-1 OMI Administered as a Booster to Adults Aged 19 Years Old and Above
Latest Information Update: 19 Nov 2024
At a glance
- Drugs AdCLD-CoV19 (Primary) ; Tozinameran/famtozinameran
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Sponsors Cellid Company
Most Recent Events
- 15 Nov 2024 Planned End Date changed from 1 Oct 2025 to 1 Nov 2025.
- 15 Nov 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Mar 2025.
- 15 Nov 2024 Status changed from recruiting to active, no longer recruiting.